BioSpace News Archive

A Kenilworth, NJ, R&D campus that formerly served as Merck’s global headquarters is now set to reopen and become the Northeast Science and Technology (NEST) Center.

Neurologist David Weisman, with financial ties to the companies, was removed from the FDA’s upcoming advisory committee meeting slated to consider Leqembi’s traditional approval.

Biogen, and partner Denali, are discontinuing the Phase III LIGHTHOUSE study of BIIB122 in Parkinson’s disease due to the trial’s long timeline and complexity.

In a lawsuit filed Tuesday in federal district court, Merck claimed that the price negotiation program laid out in the Inflation Reduction Act violates the U.S. Constitution.

While approved in non-small cell lung cancer, Keytruda failed to provide benefit for the TKI-resistant, EGFR-mutant subtype of the disease.

Ascentage Pharma announced that for the second consecutive year, it has released updated data of APG-2449, a novel FAK/ALK/ROS1 tyrosine kinase inhibitor developed by Ascentage Pharma, in patients with non-small cell lung cancer, in a Poster Discussion session at the 59th American Society of Clinical Oncology Annual Meeting.

AccuStem Sciences, Inc., a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced the establishment of a joint clinical collaboration agreement with University Hospitals.

Transgene and NEC Corporation announced that new data have been presented on TG4050, an individualized neoantigen cancer vaccine, at the American Society of Clinical Oncology Annual Meeting in Chicago, IL. TG4050 is based on Transgene’s myvac® platform and powered by NEC’s cutting-edge AI capabilities.

OSE Immunotherapeutics SA presented a poster and a publication in abstract book featuring Tedopi®, an immunotherapy activating tumor specific T-cells, in non-small cell lung cancer and in ovarian cancer at the 2023 American Society of Clinical Oncology Annual Meeting held June 2 - 6.

DeepX Diagnostics Inc. announced that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration for teledermatology screening of suspect skin cancer lesions in the United States.